• Logo
  • SBMUJournals

Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology

Mohammad Rostami-Nejad, Sina Rezaei Tavirani, Vahid mansouri, Somayeh Jahani-Sherafat, Hamideh Moravvej Farshi
66

Views

PDF

Abstract

Aim: Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology.

Background: Colon cancer is one of lethal cancer in men and women. Treatment in advanced colon cancer is difficult and survival rate is low.

Methods: Gene expression profiles of children patients with non-preforated appendicitis in comparison with the samples with non- appendicitis abdominal pain are analysis via protein – protein interaction PPI and the critical compounds are introduced by STITCH.

Results: Six critical genes including MAPK3, AKT1, SRC, TP53, GAPDH, and ALB were identified as a possible biomarker panel related to colon cancer grade II to III transition. Among these critical genes roles of MAPK3, AKT1, SRC, TP53 are highlighted.

Conclusion: It was concluded that target therapy to regulate SRC and TP53 may be the effective therapeutic way to treatment of colon cancer and more researches in necessary to design drugs for these purposes.

Keywords: Colon cancer, gene, biomarker.

(Please cite as: Rostami-Nejad M, Rezaei Tavirani S, Mansouri V, Jahani-Sherafat S, Moravvej Farshi H. Gene expression profile analysis of colon cancer grade II into grade III transition by using system biology. Gastroenterol Hepatol Bed Bench 2019;12(1):60-66).


Keywords

Colon cancer, gene, biomarker.

References

Markle B, May EJ, Majumdar AP. Do nutraceutics play a role in the prevention and treatment of colorectal cancer? Cancer and Metastasis Rev 2010;29:395-404.

Kanwar SS, Poolla A, Majumdar AP. Regulation of colon cancer recurrence and development of therapeutic strategies. World J gastrointest Pathophysiol 2012;3:1.

Aghili M, Izadi S, Madani H, Mortazavi H. Clinical and pathological evaluation of patients with early and late recurrence of colorectal cancer. Asia Pac J Clin Oncol 2010;6:35-41.

Yamamoto T, Hiroi A, Itagaki H, Kato Y, Iizuka B, Itabashi M, et al. Well-differentiated adenocarcinoma associated with ulcerative colitis. SAGE Open Med Case Rep 2017;5:2050313X17692902.

Hamzehzadeh L, Yousefi M, Ghaffari S-H. Colorectal Cancer Screening: A Comprehensive Review to Recent Non-Invasive Methods. Int J Hematol Oncol Stem Cell Res 2017;11:250.

Nomura DK, Dix MM, Cravatt BF. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 2010;10:630.

Shiromizu T, Adachi J, Watanabe S, Murakami T, Kuga T, Muraoka S, et al. Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Pro Res 2013;12:2414-21.

Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nat 2012;487:330.

Shiromizu T, Kume H, Ishida M, Adachi J, Kano M, Matsubara H, et al. Quantitation of putative colorectal cancer biomarker candidates in serum extracellular vesicles by targeted proteomics. Sci Rep 2017;7:12782.

Kit OI, Vodolazhsky DI, Kutilin DS, Enin YS, Gevorkyan Y, Kharin LV, et al. A proteomics analysis reveals 9 up regulated proteins associated with altered cell signaling in colon cancer patients. Protein J 2017;36:513-522.

Liang B, Li C, Zhao J. Identification of key pathways and genes in colorectal cancer using bioinformatics analysis. Med Oncol 2016;33:111.

Tavirani MR, Mansouri V, Tavirani SR, Tackallou SH, Rostami-Nejad M. Gliosarcoma Protein-Protein Interaction Network Analysis and Gene Ontology. Int J Cancer Management. 2018;11: e65701.

Asadzadeh-Aghdaee H, Shahrokh S, Norouzinia M, Hosseini M, Keramatinia A, Jamalan M, et al. Introduction of inflammatory bowel disease biomarkers panel using protein-protein interaction (PPI) network analysis. Gastroenterol Hepatol Bed Bench. 2016;9:S8-S13.

Safari-Alighiarloo N, Rezaei-Tavirani M, Taghizadeh M, Tabatabaei SM, Namaki S. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. Peer J 2016;4:e2775.

Rezaei-Tavirani M, Rezaei-Tavirani S, Mansouri V, Rostami-Nejad M, Rezaei-Tavirani M. Protein-Protein Interaction Network Analysis for a Biomarker Panel Related to Human Esophageal Adenocarcinoma. Asia Pacific J Cancer Prev 2017;18:3357.

Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013;29:661-3.

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 2009;25:1091-3.

Rahimian G, Sanei MH, Shirzad H, Azadegan-Dehkordi F, Taghikhani A, Salimzadeh L, et al. Virulence factors of Helicobacter pylori vacA increase markedly gastric mucosal TGF-β1 mRNA expression in gastritis patients. Micro Patho 2014;67:1-7.

Baba Y, Nosho K, Shima K, Meyerhardt J, Chan A, Engelman J, et al. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. British J Cancer 2010;103:1025.

Li X-L, Zhou J, Chen Z-R, Chng W-J. P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. World J Gastroenterol 2015;21:84.

Ryan KM, Phillips AC, Vousden KH. Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol 2001;13:332-7.

Farnood A, Naderi N, Moghaddam SJ, Noorinayer B, Firouzi F, Aghazadeh R, et al. The frequency of C3435T MDR1 gene polymorphism in Iranian patients with ulcerative colitis. Int J Colorectal Dis. 2007;22:999-1003.

Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res2008;1:369-75.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Molecular Cancer Ther 2009;8:834-43.

Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nat 2007;448:439.

Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. New England J Med 2011;365:611-9.

Chen J, Elfiky A, Han M, Chen C, Saif MW. The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer 2014;13:5-13.

Fan LC, Teng HW, Shiau CW, Tai WT, Hung MH, Yang SH, et al. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Oncotarget 2016;7:64136.

Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011;2011:865819.

Gargalionis AN, Karamouzis MV, Papavassiliou AG. The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer 2014;134:2019-29.

Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83.




DOI: https://doi.org/10.22037/ghfbb.v0i0.1518